**INFORMATION DISCLOSURE CITATION** 

several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

604-756

10/555,757

APPLICANT

HARBIGE et al FILING DATE

GROUP

November 7, 2005

Unassigned

**U.S. PATENT DOCUMENTS** 

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/B.H/	2,077,371	04/1937	Relneck et al			
/ <del></del>	2,617,791	11/1952	Snelling, et al			
	3,082,228	03/1963	Sutherland et al			
	3,158,541	11/1964	Sutherland et al			
	3,558,656	01/1971	Pfieffer et al			
	3,658,555	04/1972	Menz et al			
***************************************	3,671,557	06/1972	Pfieffer et al			
8	3,671,563	06/1972	Pfieffer et al			
	3,676,472	07/1972	Zilliken et al			
	3,748,348	07/1973	Sreenivasan, et al	-		
0000	3,855,254	12/1974	Haighton et al			
	3,862,972	01/1975	Heslinga et al			
	3,972,907	08/1976	Baran et al			
	4,048,202	09/1977	Beek et al			
	4,181,670	01/1980	Liang et al			
90000	4,607,052	08/1986	Mendy et al			
0000	4,701,468	10/1987	Mendy et al			
0000	4,701,469	10/1987	Mendy et al			
000	4,832,975	05/1989	Yang			
	4,851,343	07/1989	Herbert et al			
	4,867,965	09/1989	Ciaudelli			
	4,876,107	10/1989	King et al			
	4,938,984	07/1990	Traitler et al			
8000	5,008,126	04/1991	Klenmann et al			
	5,077,312	12/1991	Shoyab et al			
000	5,151,291	09/1972	Tokairin et al			
	5,227,403	07/1993	Seto et al			
	5,306,730	04/1994	Nagai et al			
800	5,583,159	12/1996	Horrobin et al			
0000	5,618,955	04/1997	Mechoulam et al			
	5,658,767	08/1997	Kyle et al			
	5,661,180	08/1997	DeMichele et al			
	5,663,202	09/1997	Horrobin et al			
1000000	5,668,174	09/1997	Kawagishi et al	- · · · · · · · · · · · · · · · · · · ·		_
	5,674,901	10/1997	Cook et al			
	5,753,702	05/1998	Bednar et al			
00000	5,776,913	07/1998	Olgilvie et al			
0000	5,834,512	11/1998	Akimoto et al			
	5,837,731	11/1998	Vaddadi			
/R.H./	5,869,537	03/1999	Schreiner et al			

\*Examiner Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial a this form with next communication to application.

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

604-756

10/555,757

**APPLICANT** 

**HARBIGE** et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

**November** 7, 2005

Unassigned

Examiner	/Raymond He	nlev lii/	Date Considered	<u> </u>	04/05/2010	
R.H./	6,858,416	02/2005	Murkerji et al			
	6,852,757	02/2005	Jerome et al			
	6,841,573	01/2005	Llewellyn			
00	6,528,040	03/2003	Pearson et al			
	6,689,812	02/2004	Peet et al			
	6,864,242	03/2005	Ernest			
8	6,677,470	01/2004	Saebo et al			
000	6,673,840	01/2004	Oh et al			
- N	6,630,157	10/2003	Horrobin et al			
	6,624,195	09/2003	Horrobin			
	6,576,252	06/2003	Schwartz et al			
	6,566,543	05/2003	Mechoulam et al			
	6,555,579	04/2003	Kritchevsky			
	6,537,750	03/2004	Shorrosh			
	6,528,040	03/2003	Pearson et al			
	6,495,536	12/2002	Masui et al			
	6,479,544	11/2002	Horrobin			
1	6,479,070	11/2002	Cain et al			
8	6,426,367	07/2002	Das			
	6,426,100	07/2002	Watkins et al			
*	6,410,288	06/2002	Knutzon et al			
<del>d</del>	6,410,078	06/2002	Cain et al			
-	6,361,806	03/2002	Allen et al			
-	6,340,705	01/2002	Obukowicz et al			
100	6,340,485	01/2002	Coupland et al			•
	6,331,568	12/2001	Horrobin et al			
	6,306,908	10/2001	Carlson et al			
8	6,262,119	07/2001	Ferrante et al			
	6,214,372	04/2001	Jerome et al			
8	6,201,022	03/2001	Mease et al			
	6,184,251	02/2001	Stordy et al			
8	6,080,787	06/2000	Carlson et al			
8	6,051,754	04/2000	Knutzon et al			
8	6,020,376	02/2000	Pariza et al			
	6,015,798	01/2000	Ogilvie et al			
88	5,990,163	11/1999	Evans et al			
-	5,981,588	11/1999	Akimoto et al			
<u> </u>	5,968,809	10/1999	Knutzon et al			
	5,922,345 5,962,712	10/1999	DeMichele et al	<del></del>		
\H./	5,914,347	06/1999	Grinda Horrobin et al			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

604-756

10/555,757

**APPLICANT** 

HARBIGE et al

(Use several sheets if necessary)

FILING DATE TC/A.U.

**November 7**, 2005

Unassigned

₹.H./	2001/0047036	11/2001	Vanderhoof et al	
	2002/0022658	02/2002	Das	
	2002/0051964	05/2002	Surai et al	
	2002/0065319	05/2002	Horrobin	
000	2002/0072539	06/2002	Mechoulam et al	
1	2002/0081366	06/2002	Cain et al	
	2002/0082436	06/2002	Jerome et al	
	2002/0198177	12/2002	Horrobin	
	2003/0013759	01/2003	Das	
	2003/0031753	02/2003	Watkins et al	
000	2003/0032674	02/2003	Hwang	
000	2003/0045578	03/2003	Horrobin	
000	2003/0166723	09/2003	Nakajima et al	
	2004/0014810	01/2004	Horrobin et al	
	2004/0019109	01/2004	Owman et al	
	2004/0039058	02/2004	Ursin et al	
	2004/0043963	03/2004	Wadstein	
0000	2004/0048926	03/2004	Hoffman et al	
0000	2004/0048927	03/2004	Horrobin	
000000	2004/0096468	05/2004	Changaris	
	2004/0102519	05/2004	Llewellyn	
	2004/0162348	08/2004	Peet et al	
00000	2004/0171688	09/2004	Bar-Tana	
00000	2004/0208939	10/2004	Sears et al	
00000	2004/0220081	11/2004	Kreitz et al	
900000	2004/0229950	11/2004	Vanderhoek	
0000	2004/0248763	12/2004	Freeman et al	
	2004/0266874	12/2004	Akimoto et al	
00000	2005/0009779	01/2005	Killiaan et al	
	2005/0027004	02/2005	Kyle et al	
000000	2005/0042256	02/2005	Decombaz et al	
00000	2005/0123479	06/2005	Ferrante	
	4,701,469 A	10/1987	Mendy et al	
	2003/045460 A	03/2003	Fogelman et al	
0000	3,993,775	11/1976	Williams	
R.H./	2004/0209953 A1	10/2004	Wai Lee	

FOREIGN PATENT DOCUMENTS

						TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
/R.H./	EP 0490 561	03/1996	EP				
/R.H./	EP 0 568 608	09/2000	EP				
/ PCIV No.	1		1				

\*Examiner /Raymond Henley Iii/ Date Considered 04/05/2010

\*Examiner

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

604-756

10/555,757

**APPLICANT** 

**HARBIGE** et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

November 7, 2005

Unassigned

B <sub>a</sub> H/	EP 0 679 057	08/1999	EP	
	EP 0 707 850	04/1996	EP	
	EP 0 711 503	05/1996	EP	
	EP 0 766 961	04/1997	EP	
-	EP 0 796 238	05/2000	EP	X
800	EP 0 790 056	08/1997	EP	
000	EP 0 800 584	05/2003	EP	
	WO 96/40106	12/1996	WO (Equivalent to EP 0831805)	
	EP 0 891 773	01/1999	EP	X
-	EP 0 920 300	04/2003	EP	
-8	EP 0 956 011	06/2002	EP	
	EP 0 956 013	04/2003	EP	
	WO 98/46763	10/1998	WO (Equivalent to EP 0975766)	
	EP 0 994 705	03/2004	EP	
	WO 98/46764	10/1998	WO (Equivalent to EP 0996732)	
8	WO 98/46765	10/1998	WO (Equivalent to EP 1007691	
8	EP 1 035 846	07/2002	EP	X
000	EP 1 077 061	02/2001	EP	X
	EP 1 091 659	05/2002	EP	X
	EP 1 129 711	01/2004	EP	
	WO 00/34791	06/2000	WO (Equivalent to EP 1137949)	
	WO 00/40705	07/2000	WO (Equivalent to EP 114252)	X
	WO 01/17524	03/2001	WO (Equivalent to EP 1214067)	
	WO 01/13733	03/2001	WO (Equivalent to EP 1221861)	
	EP 1 221 867	11/2004	EP	
	EP 1 292 288	09/2004	EP	
	EP 1 325 747 A2	07/2003	EP	
	EP 1 325 747 A3	07/2003	EP	
	EP 1 342 787	09/2003	EP	
	WO 02/092073	11/2002	WO (Equivalent to EP 1392278)	
800	WO 02/05849	01/2002	WO (Equivalent to EP 1476171)	
	WO 03/075670	09/2003	WO (Equivalent to EP 1489915)	
	EP 1506778	02/2005	EP	
*	WO 03/092628	11/2003	WO (Equivalent to EP 1503715)	
8	GB 1 490 603	11/1977	GB	
	GB 2 409 644	07/2005	GB	
8000	DE 100 29 562	03/2001	DE	X
*	DE 19503993	08/1996	DE	X
8	WO 98/16215	04/1998	WO	
	WO 00/12720	03/2000	WO	
(.H./	WO 00/09476	02/2000	WO	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

INFO	RMATION DISCLOSURE	ATTY.	DOCKET NO.	SERIAL NO.					
	CITATION	604-	756	10/555,75					
		APPLICANT							
			HARBIGE et al						
(1	Use several sheets if necessary)		DATE	TC/A.U.					
		Nove	ember 7, 2005	Unassigned					
<del></del>		1101	1, 2003	Ullassigii	<u>cu</u>				
	WO 00/21524	04/2000	WO						
/- <del>   - - -/</del>	WO 00/44360	08/2000	WO						
	WO 00/53637	09/2000	WO						
	WO 00/74669	12/2000	WO						
	WO 01/10989	02/2001	WO						
	WO 01/17366	03/2001	WO						
-	WO 02/047493	06/2002	WO						
	WO 03/013276	02/2003	WO						
	WO 02/096408	12/2002	WO						
	WO 02/102757	12/2002	WO						
	WO 2003/043972	05/2003	WO						
	WO 03/075003	09/2003	WO						
	WO 2004/012753	02/2004	· WO						
	WO 2004/024136	03/2004	WO						
	WO 2004/028529	04/2004	WO						
<del></del>	WO 2004/084882	10/2004	WO						
	WO 2004/105517	12/2004	WO	-					
	WO 2005/037848	04/2005	WO						
	WO 2005/063231	07/2005	WO						
	WO 90/12080	10/1990	WO						
	WO 96/05164	02/1996	WO						
	WO 97/04127	02/1997	WO						
	WO 98/16215	04/1998	WO						
	WO 98/44917	10/1998	WO						
	WO 03/013497 A	02/2003	WO						
-	WO 01/97793 A	12/2001	WO						
	EP 0 609 078 A	08/1994	EP						
	EP 0 505 817 A	09/1992	EP						
	WO 2005/018632 A1	03/2005	WO						
	WO 01/97793 A2	12/2001	WO						
/R.H./	WO 99/51560 A1	10/1999	WO						
<del>/                                      </del>	OTHER DOCL		ncluding Author, Title, Date, P	ertinent pages	, etc.)	<del>.</del>			
$\overline{R.H.}$			0/567,778, filed February 9, 2006 (						
8	Co-pending Application	Serial No. 1	1/791,606, filed May 25, 2007 (Att	torney Docket No	. 604-807).				
	Co-pending Application	Serial No. 1	1/885,255, filed August 29, 2007 (	Attorney Docket	No. 504-812).				
			matic approach"; Inform; Vol. 6:9,						
			ng scientific advance into consumer						
700000			bsorption and lymphatic transport of						
	61 (1995).		ence on intramolecular triacylglyce						
/R.H./	Christensen, M.S., et al;		of triglycerides with defined or rai	ndom structure by	rats with biliar	y and pancreatic			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

diversion"; Lipids; Vol. 30, No. 6, pp. 521-526 (1995).

/Raymond Henley Iii/

\*Examiner

04/05/2010

∂ Sheet	6 of 7		PTO/SB/08a
INFO	RMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.
	CITATION	604-756	10/555,757
		APPLICANT	
		HARBIGE et al	
(1	Use several sheets if necessary)	FILING DATE	TC/A.U.
		November 7, 2005	Unassigned
/R.H./	108-110 (1996).  Dehesh, K., "Production of	f high levels of 8:0 and 10:0 fatty acids	tions on lipid nutrition"; Nutr. Rev.; Vol. 54, No. 4, pp in transgenic canola by overexpression of Ch FatB2, a
		uphea Hookeriana"; The Plant Journal	
		nd assimilation"; Lipid Technology; pp. red lipids allow fat"; Inform Vol. 8, No	
000000000000000000000000000000000000000	Ikeda I., et al; "Lymphatic		ontaining medium-chain fatty acids and linoleic acid,
000	Jandacek, R.J., et al; "The		on of triglycerides with octanoic acid in the 1 and 3
000000000000000000000000000000000000000		tinal absorption of octanoic, decanoic,	and linoleic acids: Effect of triglyceride structure"; An
000000			atients"; Annals of Surgery; Vol. 223, No. 3, pp. 316-33
		Lipids: Fats of the Future"; Food Tech	
			tabolism"; Nutr. Biochem, Vol. 6, pp. 172-178 (1995).
	acids"; Exp. Molec. Pathol	; Vol. 6, pp. 394-401 (1967).	osclerosis Part 10. Influence of specific saturated fatty
	fats"; Med. Pharmacol. Ex	p.; Vol. 12, pp. 315-320 (1965).	osclerosis VII. Influence of naturally occurring saturate
00000000	lard"; Atherosclerosis; Vol	. 27, pp. 339-345 (1977).	sclerosis Part 15. Randomized butter and randomized
00000000	oil"; Atherosclerosis; Vol.	41, pp. 279-284 (1982).	cholesterol free diets. Part 10. Cocoa butter and palm
D000000000	Kritchevsky, D. et al; "Infl (1996).	uence of triglyceride structure on expe	rimental atherosclerosis in rabbits"; FASEB J 10, A187
000000000000000000000000000000000000000		diets 5. Comparison of peanut, corn, b	and Wissler RW. 1976. Experimental atherosclerosis in putter and cocon ut oils. Exp. Molec. Pathol. 24: 375-
000000000000000000000000000000000000000	Kritchevsky, D., et al; "Inf (1995).	luence of triglyceride structure on expe	erimental atherosclerosis in rabbits"; FASEB J 9, A320
000000000000000000000000000000000000000	Kritchevsky,k D., et al; "T 249-252 (1976).	hyroid hormone and experimental ather	rosclerosis in rabbits"; Atherosclerosis; Vol. 23, pp.
		uence of positional distribution of fatty	acids in native, interesterified and structure-specific

fractions as related to their glycerol esterification: a short-term (postprandial) and long-term study in healthy humans"; Am J. Clin Nutr.; Vol. 62, pp. 1193-1200 (1995). Small, D.M.; "The effects of glyceride structure on absorption and metabolism"; Annu. Rev. Nutr.; Vol. 11, pp. 413-434 /R.H./ (1991).

Metolli, A.M., et al; "Medium-chain lipds: new sources, uses"; *Inform*; Vol. 8, No. 6, pp. 597-603 (1997).

Mattson, F.H., et al; "The digestion and absorption of triglycerides"; J. Biol. Chem.; Vol. 239, pp. 2772-2777 (1964)

Myher, J.J., et al; "Acylglycerol Structure of peanut oils of different atherogenic potential"; Lipids; Vol. 12; pp. 765-878

Sadou, H. et al; "Differential incorporation of fish-oil eicosapentaenoate and docosahexaenoate into lipds of lipoprotein

/Raymond Henley lii/ \*Examiner

Date Considered

04/05/2010

Sheet	7 of 7		PTO/SB/08a		
INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.	SERIAL NO.		
		604-756	10/555,757		
		APPLICANT			
		HARBIGE et al			
(Use several sheets if necessary)		FILING DATE	TC/A.U.		
		November 7, 2005	Unassigned		
	concentrations in humans	'; Am. J. Clin. Nutr.; Vol. 61, pp. 48-55	• • •		
	concentrations in humans	'; Am. J. Clin. Nutr.; Vol. 61, pp. 48-55			
	Miles, E.A., et al; "The in function in healthy young	fluence of different combinations of γ-l male subjects"; <i>British Journal of Nutr</i>	inolenic acid, stearidonic acid and EPA on immune cition; Vol. 91, pp 893-903 (2004).		
	McCormick, J.N., et al; "Immunosuppressive effect of linolenic acid"; <i>The Lancet</i> ; p 508 (1977).  Demmelmair, H., et al; "Influence of formulas with borage oil or borage oil plus fish oil on the arachidonic acid statu premature infants"; <i>Lipids</i> , Vol. 36, No. 6; pp 555-566 (2001).				
0000		fatty acids in breast milk of atopic mot n"; European Journal of Clinical Nutri	hers: comparison with non-atopic mothers, and effect of <i>tion</i> ; Vol. 54, pp. 234-238 (2000).		
ĕ	Leventhal L. Let al: "Treatment of Rheumatoid Arthritis with Blackcurrant Seed Oil": British Journal of Rheum				

8	premature infants"; <i>Lipids</i> , Vol. 36, No. 6; pp 555-566 (2001).
000000000000000000000000000000000000000	Thijs, C., et al; "Essential fatty acids in breast milk of atopic mothers: comparison with non-atopic mothers, and effect of borage oil supplementation"; European Journal of Clinical Nutrition; Vol. 54, pp. 234-238 (2000).
000000000000000000000000000000000000000	Leventhal, L.J., et al; "Treatment of Rheumatoid Arthritis with Blackcurrant Seed Oil"; <i>British Journal of Rheumatology</i> ; Vol. 33, pp. 847-852 (1994).
	Zurier, R.B., et al; "Gamma-Linolenic Acid Treatment of Rheumatoid Arthritis"; Arthritis & Rheumatism; Vol. 39, No. 11, pp. 1808-1817 (1996).
000000000000000000000000000000000000000	Patent Abstracts of Japan, Vol. 1995, No. 01, 28 February 1995 & JP 06 279311 A (Sagami Chem Res Center; others: 01), 04 October 4, 1994 (Abstract).
	Patent Abstracts of Japan, Vol. 1996, No. 03, 29 March 1996 & JP 07 309773 A (Sagami Chem Res Center; others: 01), 28 November 1995 (Abstract).
	Mechoulam, R., et al; "Cannabinoids and brain injury: therapeutic implications"; <i>Trends in Molecular Medicine</i> ; Vol. 8, No. 2; pp. 58-61 (2002) XP-002381881.
	Database Biosis (Online), Biosciences Information Service, Philadelphia, PA, USA; March 2003; Rockwell C.E., et al; "Inhibition of interleukin-2 (IL-2) by the endogenous cannabinoid, 2-arachidonyl glycerol, is partly mediated through peroxisome proliferators-activated receptor-gamma (PPAR-gamma)"; Database accession no. PREV200300230725 abstract & <i>Toxicological Sciences</i> , Vol. 72, No. s-1, March 2003, p. 328, 42 <sup>nd</sup> Annual Meeting of the Society of Toxicology; Salt Lake City, UT, USA; March 9-13, 2003, ISSN: 1096-6080.
000000000000000000000000000000000000000	Database Embase (Online) Elsevier Science Publishers, Amsterdam, N1; 2005, Kaplan, B. L.F., et al; "2-Arachidonoyl-glycerol suppresses interferon-γ production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2", XP-002381886 (abstract); <i>Journal of Leukocyte Biology</i> ; Vol. 77 pp. 966-974 (2005).
000000000000000000000000000000000000000	Ouyang, Y., et al; "Suppression of Interleukin-2 by the Putative Endogenous Cannabinoid 2-Arachidonyl-Glycerol is Mediated through Down-regulation of the Nuclear Factor of Activated T Cells"; <i>Molecular Pharmacology</i> ; Vol. 53, pp. 676-683 (1998) XP-002381882.
/R.H./	Venderova, K., et al; "Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus"; Experimental Neurology; Vol. 194, pp. 294-287 (2005).

	1		1
*Examiner	/Raymond Henley Iii/	Date Considered	04/05/2010